For example, RET alterations were detected in 4 of 5 sampled medullary thyroid carcinomas (80%), 4 of 54 ovarian epithelial carcinomas (7.4%), and 27 of 527 lung carcinomas (5.1%), highlighting the rarity of RET alterations in breast cancer relative to other known RET-driven malignancies. This evidence concerns the gene RET and lung carcinoma.